Skip to main content
. 2015 Oct 21;10(10):e0140843. doi: 10.1371/journal.pone.0140843

Table 4. Cost-effectiveness: base case results.

Value (discounted) Standard therapy Belimumab Difference
Life years 18.99 19.76 0.77
QALYs a 10.78 11.31 0.538
Costs € 125,234 € 142,921 € 17,688
ICUR b € 32,859
ICER c € 22,990

a QALYs: Quality Adjusted Life Years

b ICUR: Incremental Cost-Utility Ratio

c ICER: Incremental Cost-Effectiveness Ratio